Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.8K
Overview
51.8K
What are Viruses?00:50

What are Viruses?

128.3K
Overview
128.3K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Sustainable Development01:43

Sustainable Development

15.2K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
15.2K
Introduction to Virus01:28

Introduction to Virus

1.7K
Viruses are unique biological entities that blur the boundary between living and non-living systems. Although they lack cellular structure and metabolic processes, they can exhibit characteristics of life when infecting a host. Their defining feature is a nucleic acid core, composed of either DNA or RNA, encapsulated within a protein coat called a capsid. This simple structure allows them to invade host cells and use their machinery for replication efficiently.Viral Structure and...
1.7K
Viruses of Archaea01:29

Viruses of Archaea

520
Archaeal viruses play a crucial role in the ecosystems of extremophilic archaea, particularly those belonging to the phyla Euryarchaeota and Crenarchaeota. By shaping host evolution and facilitating gene transfer, these viruses influence microbial communities and contribute to genetic diversity in extreme environments. The archaea they infect thrive in acidic hot springs and hydrothermal vents characterized by high temperatures and low pH. Archaeal viruses exhibit remarkable structural...
520

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transgene Expression Kinetics and Replication Potential of Recombinant Adenovirus Serotype 4 in a Mouse Model and its Use as a Herpes Simplex Virus Vaccine.

bioRxiv : the preprint server for biology·2026
Same author

Immunization with Herpes Simplex Virus Nanoparticles Targeting Both Attachment and Fusion Protect Against Infection.

bioRxiv : the preprint server for biology·2026
Same author

Intranasal Replicating Adenovirus type 4-SARS-CoV-2 Recombinants Induce Superior Immune Response Durability and Efficacy in Preclinical Testing Compared to Standard Intramuscular Vaccines.

bioRxiv : the preprint server for biology·2026
Same author

Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testing.

iScience·2026
Same author

Enhancing, controlling, and sterilizing dengue immunity and the development of broadly protective responses.

medRxiv : the preprint server for health sciences·2026
Same author

Targeted deep sequencing identifies mosaicism in patients with immune dysregulation.

The Journal of allergy and clinical immunology·2026
Same journal

Peptidomics in the Spotlight: Advanced Sample Treatment Techniques and Analytical Insights.

Advances in experimental medicine and biology·2026
Same journal

Methods for the Investigation of Protein-Ligands Interactions.

Advances in experimental medicine and biology·2026
Same journal

Sample Preparation Strategies for Microbial Cell Surface Proteomics: Integrating Shaving and Shotgun Approaches.

Advances in experimental medicine and biology·2026
Same journal

Proteomic Sample Preparation for the Petroleum Industry: A Biocorrosion Case Study.

Advances in experimental medicine and biology·2026
Same journal

Proteomic and Functional Comparison of Extracellular Vesicles from Wild-Type and Lyn-Deficient Stromal Cells.

Advances in experimental medicine and biology·2026
Same journal

Proteomic Analysis of Histone Sequence Variants and Post-translationally Modified Forms.

Advances in experimental medicine and biology·2026
See all related articles

Related Experiment Video

Updated: Feb 9, 2026

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

41.3K

Vaccine Development for Epstein-Barr Virus.

Jeffrey I Cohen1

  • 1Laboratory of Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. jcohen@niaid.nih.gov.

Advances in Experimental Medicine and Biology
|June 14, 2018
PubMed
Summary
This summary is machine-generated.

Developing an Epstein-Barr virus (EBV) vaccine is crucial. Newer gp350 formulations and additional viral components may enhance vaccine effectiveness against EBV-associated diseases like mononucleosis and cancers.

Keywords:
Burkitt lymphomaEpstein-Barr virusGastric carcinomaHodgkin lymphomaInfectious mononucleosisNasopharyngeal carcinoma

More Related Videos

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

4.7K
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

13.4K

Related Experiment Videos

Last Updated: Feb 9, 2026

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

41.3K
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

4.7K
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

13.4K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Epstein-Barr virus (EBV) causes infectious mononucleosis and is linked to cancers (e.g., Hodgkin lymphoma, Burkitt lymphoma) and multiple sclerosis.
  • Currently, no EBV vaccine is available, despite the virus's significant health impact.

Purpose of the Study:

  • To review the potential of EBV vaccines, focusing on gp350 antigen formulations.
  • To identify the need for clinical trials evaluating EBV vaccines for preventing infectious mononucleosis and EBV-associated malignancies.

Main Methods:

  • Review of existing literature on EBV, infectious mononucleosis, and gp350 vaccine trials.
  • Analysis of potential vaccine strategies, including multimeric gp350, virus-like particles, and nanoparticles.
  • Discussion of the feasibility and importance of future clinical trials.

Main Results:

  • Monomeric gp350 showed limited success in reducing infectious mononucleosis incidence.
  • Advanced gp350 formulations (multimeric, virus-like particles, nanoparticles) may offer improved efficacy.
  • Vaccines incorporating additional viral proteins could enhance protection.

Conclusions:

  • Further clinical trials are essential to assess EBV vaccine efficacy in preventing infectious mononucleosis and post-transplant lymphoproliferative disease.
  • An effective EBV vaccine could prevent significant morbidity, including debilitating fatigue and EBV-associated cancers.
  • While challenging, trials targeting EBV-associated Hodgkin lymphoma, multiple sclerosis, and Burkitt lymphoma are feasible and warranted.